
The role of MRI in the diagnosis and management of multiple sclerosis (MS) has depended upon assessment of discrete lesions. Over the past several years, the importance of whole brain measurement—atrophy—as one of the best predictors of clinical status in patients has been appreciated. Recent investigations have utilized brain atrophy measures for critical clinical evaluation of issues such as early diagnosis and the role of neutralizing antibodies. Advances in the use of MRI to include brain atrophy may soon become routine in the management of patients with MS.
 |
 |